Johnson Pharmacare Intrinsic Value
Johnson Pharmacare (JOHNPHARMA) median intrinsic value is ₹0.29 from 1 valuation models (range ₹0–₹0), vs current price ₹0.46 — -37.0% downside (Trading Above Calculated Value), margin of safety -58.6%. Check JOHNPHARMA market capitalization to track the company's total market size over time.
JOHNPHARMA Valuation Methods Summary — DCF, Graham Number & P/E
Johnson Pharmacare intrinsic value across 1 models vs current price ₹0.46 — upside/downside and value range per method. For current market price and key ratios, visit Johnson Pharmacare screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Revenue Multiple Method | revenue | ₹0.29 | ₹0.26 - ₹0.32 | -37.0% | Revenue/Share: ₹0.36, P/S: 0.8x |
JOHNPHARMA Intrinsic Value vs Market Price — All Valuation Models
Johnson Pharmacare fair value range ₹0–₹0 vs current market price ₹0.46 across 1 valuation models. See JOHNPHARMA P/B ratio to compare market price against book value per share.
JOHNPHARMA Intrinsic Value Analysis — Undervalued or Overvalued?
Johnson Pharmacare median intrinsic value ₹0.29, current price ₹0.46 — Trading Above Calculated Value by 37.0%, margin of safety -58.6%.
What is the intrinsic value of JOHNPHARMA?
Based on our comprehensive analysis using 1 different valuation methods, the estimated intrinsic value of Johnson Pharmacare (JOHNPHARMA) is ₹0.29 (median value). With the current market price of ₹0.46, this represents a -37.0% variance from our estimated fair value.
The valuation range spans from ₹0.29 to ₹0.29, indicating ₹0.29 - ₹0.29.
Is JOHNPHARMA undervalued or overvalued?
Based on our multi-method analysis, Johnson Pharmacare (JOHNPHARMA) appears to be trading above calculated value by approximately 37.0%.
JOHNPHARMA Financial Health — Key Ratios vs Industry Benchmarks
Johnson Pharmacare financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.10 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Asset Turnover Ratio | 0.09x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
JOHNPHARMA Cash Flow Quality — Operating & Free Cash Flow
Johnson Pharmacare operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-2 Cr | ₹-2 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹5 Cr | ₹3 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |